ZEALAND PHARMA
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim. Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is ... marketed globally outside the US as Lyxumia:registered: by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus:registered:) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016. The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics. The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma
ZEALAND PHARMA
Industry:
Biopharma Biotechnology Health Care
Founded:
1998-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.zealandpharma.com
Total Employee:
251+
Status:
Active
Contact:
45 88 77 36 00
Email Addresses:
[email protected]
Total Funding:
1.59 B USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Global Site Tag Mobile Non Scaleable Content Organization Schema
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Healx
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
ZOE Health Study
ZOE Health Study is a biotechnology research company that offers technology to unlock the secrets of the immune system.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-02-10 | Valeritas | Valeritas acquired by Zealand Pharma | 23 M USD |
| 2019-10-23 | Encycle Therapeutics | Encycle Therapeutics acquired by Zealand Pharma | N/A |
Investors List
European Investment Bank
European Investment Bank investment in Post-IPO Debt - Zealand Pharma
Oberland Capital
Oberland Capital investment in Post-IPO Debt - Zealand Pharma
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Equity - Zealand Pharma
Idinvest Partners
Idinvest Partners investment in Venture Round - Zealand Pharma
Innovation Capital
Innovation Capital investment in Venture Round - Zealand Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-01-08 | Beta Bionics | Zealand Pharma investment in Series B - Beta Bionics | 63 M USD |
Key Employee Changes
Official Site Inspections
http://www.zealandpharma.com Semrush global rank: 723.14 K Semrush visits lastest month: 42.66 K
- Host name: 104.47.160.14
- IP address: 104.47.160.14
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091
More informations about "Zealand Pharma"
Zealand Pharma - Wikipedia
Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. [1] …See details»
Zealand Pharma - Crunchbase Company Profile
Contact Email [email protected] Phone Number 45 88 77 36 00 Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company …See details»
Zealand Pharma - LinkedIn
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a Danish biotechnology company on a mission to change lives with next generation peptide medicines.See details»
Zealand Pharma A/S - Overview, News & Similar companies
Mar 20, 2024 Explore Complete Organization Structure. Is Zealand Pharma A/S your ideal customer? Let us give you the heads up on whether it's a good time to reach out ... Phone …See details»
Zealand Pharma - Craft
Oct 29, 2024 Zealand Pharma is a biotechnology company that discovers, designs, and develops peptide-based medicines. It focuses on gastrointestinal, metabolic, and other …See details»
Zealand Pharma AS Company Profile - Overview - GlobalData
Zealand Pharma AS (Zealand Pharma) is a biotechnology company that discovers and develops peptide-based medicines. The company's pipeline products include Dapiglutide, Petrelintide, …See details»
Zealand Pharma (CPH:ZEAL) Company Profile & Description
4 days ago Company profile for Zealand Pharma A/S (CPH:ZEAL) with a description, list of executives, contact details and other key facts.See details»
Zealand Pharma - Pharmaceutical Companies Database - ICH GCP
Zealand Pharma A/S was founded in 1998 and is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines.See details»
Zealand Pharma A/S - Datanyze
Organization Head of People. Email. Phone. Reveal for Free. Chandra Slusser. Global Associate Director, - Medical Affairs (US) Email. Phone. Reveal for Free. ... [email protected]: …See details»
About us - Zealand Pharma
Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D …See details»
Zealand Pharma - 2025 Company Profile - Tracxn
Apr 25, 2025 Zealand Pharma - Developer of protein therapies for the treatment of diabetes and gastrointestinal diseases. Public Company. Raised funding over 5 rounds from 10 investors. …See details»
Investors - Zealand Pharma
2 days ago In 2024, we advanced our clinical-stage obesity portfolio, raised significant capital to further invest in our pipeline, and prepared the organization for the next phase of growth. Read …See details»
Corporate governance - About us - Zealand Pharma
Zealand’s Corporate Governance structure includes the Annual General Meeting, the Board of Directors and Committees, Corporate Management, and the rest of the organization. …See details»
Our impact - About us - Zealand Pharma
As we pursue our ambition of becoming the world’s best peptide drug discovery and development company, our impact on global health and society continues to increase.See details»
Contact - Zealand Pharma
Zealand Pharma is an international biotechnology company headquartered in Denmark. We are focused on the discovery, design, and development of innovative peptide-based medicines for …See details»
Zealand Pharma announces closing of collaboration and
1 day ago Company announcement – No. 12 / 2025. Zealand Pharma announces closing of collaboration and license agreement with Roche. Copenhagen, Denmark, May 9, 2025 – …See details»
Zealand Pharma
Feb 25, 2025 Zealand Pharma was founded in 1997 by five leading Danish scientists and was listed as a public company in 2015 on Nasdaq Copenhagen. It has since established a …See details»
Zealand Pharma increases its share capital as a result of the …
Mar 20, 2025 For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are available on the website: www.zealandpharma.com.See details»
Zealand Pharma announces closing of collaboration and license …
1 day ago Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused …See details»
Zealand Pharma increases its share capital as a result of
Mar 20, 2025 A full copy of the new and amended Articles of Association can be found at https://www.zealandpharma.com once registered with the Danish Business Authority. About …See details»